124 related articles for article (PubMed ID: 32238707)
1. Effects of Diluent Volume and Administration Time on the Incidence of Anaphylaxis Following Docetaxel Therapy in Breast Cancer.
Ishida S; Masuguchi K; Kawashiri T; Tsuji T; Watanabe H; Akiyoshi S; Kubo M; Masuda S; Egashira N
Biol Pharm Bull; 2020; 43(4):663-668. PubMed ID: 32238707
[TBL] [Abstract][Full Text] [Related]
2. Desensitization to chemotherapeutic agents.
Lieberman P; Castells M
J Allergy Clin Immunol Pract; 2014; 2(1):116-7. PubMed ID: 24565784
[No Abstract] [Full Text] [Related]
3. Re-exploring immune-related side effects of docetaxel in an observational study: Blood hypereosinophilia.
Hamdan D; Leboeuf C; Le Foll C; Bousquet G; Janin A
Cancer Med; 2019 May; 8(5):2005-2012. PubMed ID: 30854809
[TBL] [Abstract][Full Text] [Related]
4. Severe anaphylaxis caused by intravenous anti-cancer drugs.
Horita N; Miyagi E; Mizushima T; Hagihara M; Hata C; Hattori Y; Hayashi N; Irie K; Ishikawa H; Kawabata Y; Kitani Y; Kobayashi N; Kobayashi N; Kurita Y; Miyake Y; Miyake K; Oguri S; Ota I; Shimizu A; Takeuchi M; Yamada A; Yamamoto K; Yukawa N; Masuda M; Oridate N; Ichikawa Y; Kaneko T
Cancer Med; 2021 Oct; 10(20):7174-7183. PubMed ID: 34505396
[TBL] [Abstract][Full Text] [Related]
5. Single premedication dose of dexamethasone 20 mg IV before docetaxel administration.
Chouhan JD; Herrington JD
J Oncol Pharm Pract; 2011 Sep; 17(3):155-9. PubMed ID: 20447949
[TBL] [Abstract][Full Text] [Related]
6. Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose-reduced 3-weekly docetaxel for metastatic castration-resistant prostate cancer.
Hamid AA; Willson K; Vincent AD; Tamjid B; Lee M; Bergin A; Gan C; Campbell A; Stewart J; Pezaro C; Tran B; Weickhardt AJ
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e399-e404. PubMed ID: 29318740
[TBL] [Abstract][Full Text] [Related]
7. Study Protocol for Assessing the Efficacy of Compression Therapy Using Stockings and Sleeves to Prevent Docetaxel-Induced Peripheral Neuropathy in Breast Cancer Patients.
Yamanouchi K; Kuba S; Matsumoto M; Yano H; Morita M; Sakimura C; Otsubo R; Kanetaka K; Nagayasu T; Eguchi S
Acta Med Okayama; 2020 Oct; 74(5):455-459. PubMed ID: 33106704
[TBL] [Abstract][Full Text] [Related]
8. Acute infusion reactions to chemotherapeutic drugs: a single institute experience.
Muallaoglu S; Disel U; Mertsoylu H; Besen A; Karadeniz C; Taner Sumbul A; Abali H; Ozyilkan O
J BUON; 2013; 18(1):261-7. PubMed ID: 23613414
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel/cyclophosphamide chemotherapy in older patients with breast cancer.
Decoster L; Fontaine C; Vanacker L; Schallier D; De Grève J
Breast J; 2018 Jul; 24(4):695-697. PubMed ID: 29286203
[No Abstract] [Full Text] [Related]
10. Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer.
Shimura Y; Suga Y; Itai S; Iwamoto H; Takezawa Y; Yaegashi H; Izumi K; Shimada T; Sai Y; Matsushita R; Mizokami A
Anticancer Res; 2020 Aug; 40(8):4291-4297. PubMed ID: 32727756
[TBL] [Abstract][Full Text] [Related]
11. Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ; Vargo C; Vincent M; Shaver K; Phillips G; Layman R; Macrae E; Mrozek E; Ramaswamy B; Wesolowski R; Shapiro CL; Lustberg MB
Support Care Cancer; 2015 Jul; 23(7):2019-24. PubMed ID: 25519756
[TBL] [Abstract][Full Text] [Related]
12. Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.
Craig TJ; Li HH; Riedl M; Bernstein JA; Lumry WR; MacGinnitie AJ; Stolz LE; Biedenkapp J; Chyung Y
J Allergy Clin Immunol Pract; 2015; 3(2):206-212.e4. PubMed ID: 25609335
[TBL] [Abstract][Full Text] [Related]
13. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity.
Moon C; Verschraegen CF; Bevers M; Freedman R; Kudelka AP; Kavanagh JJ
Anticancer Drugs; 2000 Aug; 11(7):565-8. PubMed ID: 11036959
[TBL] [Abstract][Full Text] [Related]
14. No relation between docetaxel administration route and high-grade diarrhea incidence.
Hendrikx JJMA; Stuurman FE; Song JY; de Weger VA; Lagas JS; Rosing H; Beijnen JH; Schinkel AH; Schellens JHM; Marchetti S
Pharmacol Res Perspect; 2020 Aug; 8(4):e00633. PubMed ID: 32725720
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy-Induced Neutropenia and Outcome in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With First-Line Docetaxel.
Buttigliero C; Tucci M; Vignani F; Di Stefano RF; Leone G; Zichi C; Pignataro D; Lacidogna G; Guglielmini P; Numico G; Scagliotti GV; Di Maio M
Clin Genitourin Cancer; 2018 Aug; 16(4):318-324. PubMed ID: 29866495
[TBL] [Abstract][Full Text] [Related]
16. Successful desensitization to docetaxel after severe hypersensitivity reactions in two patients.
Reeves DJ; Callahan MJ; Sutton GP
Am J Health Syst Pharm; 2012 Mar; 69(6):499-503. PubMed ID: 22382481
[TBL] [Abstract][Full Text] [Related]
17. Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group.
Abe H; Ogawa H; Okino T; Kato M; Sako H; Sano H; Shimomatsuya T; Suwa H; Higashide S
Breast Cancer; 2009; 16(1):37-41. PubMed ID: 18493840
[TBL] [Abstract][Full Text] [Related]
18. [A clinical study of reasonable doses of docetaxel salvage therapy for patients with metastatic breast cancer].
Wu SK; Ma Y; Meng XY; Sun B; Wang T; Zhang SH; Jiang ZF; Song ST
Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):764-9. PubMed ID: 23291071
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy-induced febrile neutropenia: primary G-CSF prophylaxis indicated during docetaxel cycles.
van Dooijeweert C; van der Wall E; Baas IO
Neth J Med; 2019 Dec; 77(9):310-316. PubMed ID: 31814585
[TBL] [Abstract][Full Text] [Related]
20. A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V; Chevallier B; Kerbrat P; Krakowski I; Roche H; Misset JL; Lentz MA; Azli N; Murawsky M; Riva A; Pouillart P; Fumoleau P
Br J Cancer; 1996 Aug; 74(4):650-6. PubMed ID: 8761385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
